Use of Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura: A Single Center Experience

Authors : Emre Hafızoğlu, Vildan Ozkocaman, Fahir Özkalemkaş

Pages : 59-65

Doi:10.32708/uutfd.1635651

View : 64 | Download : 125

Publication Date : 2025-05-27

Article Type : Research Paper

Abstract :This study aimed to evaluate the efficacy and safety of eltrombopag in the outpatient clinic of the Department of Hematology, Uludag University Faculty of Medicine. Treatment responses and demographic characteristics of 25 patients diagnosed with refractory chronic immune thrombocytopenia (ITP) and receiving eltrombopag between January 2011 and March 2014 were analyzed retrospectively. Both platelet ≥30,000/mm³ and ≥50,000/mm³ values were considered as responses. Prolonged response was defined as the maintenance of platelet 50,000/mm³ values for 12 weeks or longer without the need for any additional treatment, and sustained response was defined as the maintenance of platelet 50,000/mm³ and at least 2 times the baseline values without the need for additional treatment. Twenty-five patients were evaluated. Ten patients (40%) had an initial platelet value of <15,000/mm³, and 15 (60%) had ≥15,000/mm³. The baseline median platelet value increased from 15,700/mm³ to 30,000/mm³ at week 2 and to 51,000/mm³ at week 6, and this level was maintained throughout the 85-week observation period. Thirteen (52%) patients had a sustained response, with a median follow-up of 18 months. In the study, participants were grouped according to splenectomy status, platelet <15,000/mm³, and gender, and there was no statistically significant difference in response. Eltrombopag is an effective and well-tolerated therapeutic agent in patients with chronic ITP refractory to other therapies and at increased bleeding risk. Responsiveness is independent of splenectomy, concomitant therapy, or baseline platelet values.
Keywords : Kronik immun trombositopeni, refrakter hastalık, tedavi

ORIGINAL ARTICLE URL